10X Genomics Inc reports results for the quarter ended in December - Earnings Summary

10x Genomics

15/02/2024 22:56

* 10X Genomics Inc  TXG.OQ  reported a quarterly adjusted
loss
of 41 cents​​ per share for the quarter ended in December, lower
than the same quarter last year, when the company reported EPS
of -15 cents.  The mean expectation of fifteen analysts for the
quarter was for a loss of 36 cents per share. Wall Street
expected results to range from -49 cents to -22 cents per share.
    * Revenue rose 17.8% to $183.98 million from a year ago;
analysts
expected $182.80 million. 
    * 10X Genomics Inc's reported EPS for the quarter was a loss
of 41
cents​.
    * The company reported a quarterly loss of $48.95 million.
    * 10X Genomics Inc shares had fallen by 14.1% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 5.6%
in the last three months.​ 
    * In the last 30 days, three analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for 10X Genomics Inc
is $60.00 
This summary was machine generated from LSEG data February 15 at
10:56 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.36          -0.41          Missed
 Sep. 30 2023      -0.46          -0.79          Missed
 Jun. 30 2023      -0.40          -0.53          Missed
 Mar. 31 2023      -0.37          -0.44          Missed